ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015
Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Immune evolution and therapeutic vulnerabilities in thyroid cancer: from inflammation to immune escape.Frontiers in immunology · 2026Review
- New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer.Frontiers in immunology · 2026Review
- Hashimoto's thyroiditis both promotes and protects against papillary thyroid cancer.Frontiers in endocrinology · 2026Review
- Value of a BRAFFrontiers in endocrinology · 2025Article
- Research Progress on the Immunological Correlation Between Papillary Thyroid Carcinoma and Hashimoto's Thyroiditis.Journal of immunology research · 2025Review
- Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers.Current opinion in endocrine and metabolic research · 2024Article
- Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.Diagnostic pathology · 2024Article
- Harnessing Immunity to Treat Advanced Thyroid Cancer.Vaccines · 2023Review
- Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer.BMC medical genomics · 2023Article
- Pan-cancer analysis of kinesin family members with potential implications in prognosis and immunological role in human cancer.Frontiers in oncology · 2023Article
- Cell Component and Function of Tumor Microenvironment in Thyroid Cancer.International journal of molecular sciences · 2022Review
- A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs.BMC medical genomics · 2022Article
- Immune profiling identifies CD8Frontiers in immunology · 2022Article
- Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.Frontiers in endocrinology · 2022Observational
- The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.Cells · 2021Review
- Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis.Scientific reports · 2020Article
- Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.The Journal of international medical research · 2020Article
- FoxP3 promotes lymph node metastasis in patients with papillary thyroid carcinoma complicated with Hashimoto's thyroiditis.Translational cancer research · 2020Article
- Immune Landscape of Thyroid Cancers: New Insights.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRegulatory T cells (Treg) suppress the immune reaction. The aim of the present study was to investigate the clinicopathologic significance and roles of Treg in papillary thyroid carcinoma (PTC) patients with and without Hashimoto's thyroiditis.
methodsFlow cytometry was used to detect the percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood. FoxP3+ Treg were detected by immunohistochemistry in the tumor tissues.
resultsThe percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells was significantly higher in PTC patients than that in multinodular goiter (MNG) patients. There were large numbers of tumor-infiltrating FoxP3+ Treg in primary PTC and metastatic lymph nodes tissues; however, there was no FoxP3 expression in the MNG tissues. Higher percentage of Treg both in peripheral blood and tumor tissues was associated with extrathyroidal extension and lymph nodes metastasis. The percentage of CD4+CD25+CD127low/- Treg among CD4+ T cells in peripheral blood of PTC patients with Hashimoto's thyroiditis (HT) was significantly lower, whereas the infiltration of FoxP3+ Treg in tissues of PTC with HT tended to be increased.
conclusionsWe concluded that the percentage of Treg increased in peripheral blood as well as in the tumor tissues of PTC patients compared with that of MNG patients. The high percentage of Treg was associated with aggressiveness. There may be a compensatory expansion of Treg at the sites of inflammation in tissues of PTC with HT contributing to the immune response suppression.
Indexed as
Identifiers
25387566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.